Gossamer Bio (GOSS) reprices EVP Caryn Peterson’s stock options to $0.45
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gossamer Bio, Inc. executive Caryn Peterson, EVP of Regulatory Affairs, reported a one-time repricing of multiple stock option awards effective March 19, 2026. Previously granted options were surrendered back to the company and replacement options for the same share amounts were granted with a reduced exercise price of $0.45 per share. According to the disclosure, all other terms of these options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on her ongoing service.
Positive
- None.
Negative
- None.
Insider Trade Summary
24 transactions reported
Mixed
24 txns
Insider
Peterson Caryn
Role
EVP, Regulatory Affairs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 506,250 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 440,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 375,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 125,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 157,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 157,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 126,667 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 21,167 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 18,834 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 22,784 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 9,167 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 32,334 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 506,250 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 440,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 375,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 125,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 157,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 157,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 126,667 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 21,167 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 18,834 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 22,784 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 9,167 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 32,334 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
- Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
FAQ
What insider transaction did Gossamer Bio (GOSS) report for Caryn Peterson?
Gossamer Bio reported that EVP of Regulatory Affairs Caryn Peterson exchanged several existing stock options for new options. The new awards keep the same share counts and terms but reset the exercise price to $0.45 per share under the 2019 Incentive Award Plan.
Was this Gossamer Bio (GOSS) Form 4 a stock option repricing?
Yes. The filing describes a one-time repricing of certain outstanding stock options effective March 19, 2026. Existing options were returned to the issuer and replacement options were granted at an exercise price of $0.45, with all other vesting and term provisions remaining in effect.
How does the Gossamer Bio (GOSS) option repricing affect exercise price?
The option repricing reduces the per share exercise price of the affected stock options to $0.45. While the strike price changed, the filing states that all other terms, including vesting schedules and expiration dates, continue as previously established under the 2019 Incentive Award Plan.
Do Caryn Peterson’s Gossamer Bio (GOSS) repriced options change vesting terms?
No. The filing states that, apart from the new $0.45 exercise price, all other terms remain in full force. Vesting continues to follow the original award agreements and still depends on Peterson’s continued service with Gossamer Bio on each applicable vesting date.
Under which plan were Caryn Peterson’s Gossamer Bio (GOSS) options repriced?
The repriced stock options were granted under Gossamer Bio’s 2019 Incentive Award Plan. The Form 4 explains that the one-time repricing affects certain options issued pursuant to this plan, keeping existing vesting and term conditions while lowering the exercise price to $0.45 per share.
Did the Gossamer Bio (GOSS) Form 4 show net buying or selling of common stock?
No open-market buying or selling of common stock was reported. The Form 4 only shows derivative transactions: options disposed back to the issuer and replacement option grants, resulting in neutral net buy–sell share activity according to the transaction summary provided.